Switching from Phenytoin 325 mg to Carbamazepine (Tegretol)
When switching a patient from phenytoin 325 mg to carbamazepine, initiate carbamazepine at 200 mg twice daily (400 mg/day) while simultaneously beginning a rapid phenytoin taper of 100 mg/day, completing the phenytoin withdrawal within 3-4 days, then titrate carbamazepine upward by 200 mg weekly until reaching a maintenance dose of 800-1200 mg/day. 1
Rationale for Rapid Cross-Titration
The evidence strongly supports a rapid switchover approach rather than prolonged overlap. Phenytoin is a potent enzyme inducer that significantly increases carbamazepine metabolism 2, 3. When phenytoin is present, patients require approximately twice as much carbamazepine to maintain therapeutic levels 2. This means during a slow taper, you risk both breakthrough seizures from subtherapeutic carbamazepine levels and toxicity once phenytoin is fully withdrawn.
Specific Protocol
Day 1-3: Initiation Phase
- Start carbamazepine: 200 mg twice daily (400 mg/day total) 1
- Begin phenytoin taper: Reduce by 100 mg/day 4
- Take carbamazepine with meals to minimize gastrointestinal side effects 1
Day 4: Complete Phenytoin Withdrawal
- Phenytoin should be fully discontinued by day 3-4 4
- Continue carbamazepine 400 mg/day
Week 2 Onward: Carbamazepine Titration
- Increase carbamazepine by 200 mg/day at weekly intervals 1
- Target maintenance dose: 800-1200 mg/day for adults 1
- Maximum dose: 1200 mg/day for most adults (up to 1600 mg/day in rare cases) 1
Critical Monitoring Requirements
Weeks 1-4: Intensive Phase
- Monitor carbamazepine levels at weeks 2 and 4 post-phenytoin discontinuation 4, 2
- Expect carbamazepine levels to increase by 50-100% after phenytoin withdrawal 2
- Reduce carbamazepine dose by approximately 20% within 4 weeks of completing phenytoin taper in about 60% of patients 4
Seizure Monitoring
- Track seizure frequency weekly during transition
- Research shows 95% of patients maintain or improve seizure control with this approach 5
- Only 5% experience loss of seizure control 5
Important Drug Interaction Considerations
Phenytoin is no longer recommended as first-line therapy due to its enzyme-inducing properties and adverse event profile 6, 3. The switch to carbamazepine is appropriate, though note that carbamazepine is also an enzyme inducer (though less potent than phenytoin) and may interact with:
- Corticosteroids 7
- Chemotherapy agents 3
- Oral anticoagulants (increases metabolism, reducing efficacy) 8
Common Pitfalls to Avoid
Slow phenytoin taper: Prolonging phenytoin withdrawal beyond 3-4 days creates a moving target for carbamazepine dosing and risks breakthrough seizures 4, 2
Starting carbamazepine too low: The 400 mg/day starting dose accounts for phenytoin's enzyme induction; lower doses risk inadequate seizure control 1, 4
Failing to reduce carbamazepine post-switch: Most patients (60%) will require a 20% dose reduction within 4 weeks after phenytoin is fully discontinued due to deinduction 4
Inadequate monitoring: Carbamazepine levels can double after phenytoin withdrawal; without monitoring, toxicity (drowsiness, dizziness, ataxia) is likely 2
Special Populations
Patients with Static Encephalopathy or Age ≥55
- Use slower titration (increase by 100 mg weekly instead of 200 mg)
- These patients have higher risk of moderate-to-severe adverse effects 4
- Consider extended-release formulation (Tegretol-XR) for better tolerability 1
HLA-B*15:02 Screening
- Mandatory screening before initiating carbamazepine in patients of Han Chinese descent
- Risk of Stevens-Johnson syndrome/toxic epidermal necrolysis 9
- If positive, choose alternative agent (levetiracetam or lamotrigine preferred) 6
Expected Outcomes
With this rapid switchover protocol: